# Curis Inc: financial statements, quarterly

CRIS · Nasdaq · CIK 1108205 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cris.md) · [Financials](/companies/cris/financials.md) · [Filings](/companies/cris/filings.md) · [Insiders](/companies/cris/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cris/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.8](/filings/0001108205-24-000072.md) | [2.7 d](/filings/0001108205-25-000031.md) | [2.1](/filings/0001108205-25-000046.md) | [2.5](/filings/0001108205-25-000080.md) | [2.9](/filings/0001108205-25-000107.md) | [3.3 d](/filings/0001108205-26-000043.md) | [2.4](/filings/0001108205-26-000061.md) | [2.7](/filings/0001108205-26-000118.md) | [3.2](/filings/0001108205-25-000107.md) | [1.1 d](/filings/0001108205-26-000043.md) | [0.0](/filings/0001108205-26-000061.md) | [0.0](/filings/0001108205-26-000118.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(12.4)](/filings/0001108205-24-000072.md) | [(12.2) d](/filings/0001108205-25-000031.md) | [(12.5)](/filings/0001108205-25-000046.md) | [(12.5)](/filings/0001108205-25-000080.md) | [(10.6)](/filings/0001108205-25-000107.md) | [(9.0) d](/filings/0001108205-26-000043.md) | [(10.2)](/filings/0001108205-26-000061.md) | [(8.3)](/filings/0001108205-26-000118.md) | [(6.9)](/filings/0001108205-25-000107.md) | [19.6 d](/filings/0001108205-26-000043.md) | [(11.5)](/filings/0001108205-26-000061.md) | [(9.9)](/filings/0001108205-26-000118.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(12.2)](/filings/0001108205-24-000072.md) | [(11.7) d](/filings/0001108205-25-000031.md) | [(11.9)](/filings/0001108205-25-000107.md) | [(11.8)](/filings/0001108205-25-000107.md) | [(10.1)](/filings/0001108205-25-000107.md) | [(9.6) d](/filings/0001108205-26-000043.md) | [(10.6)](/filings/0001108205-26-000118.md) | [(8.6)](/filings/0001108205-26-000118.md) | [(7.7)](/filings/0001108205-25-000107.md) | [19.4 d](/filings/0001108205-26-000043.md) | [(24.2)](/filings/0001108205-26-000118.md) | [(8.6)](/filings/0001108205-26-000118.md) |
| Diluted EPS | $ per share | [(2.13)](/filings/0001108205-24-000072.md) | not reported | [(2.05)](/filings/0001108205-25-000046.md) | [(2.03)](/filings/0001108205-25-000080.md) | [(1.70)](/filings/0001108205-25-000107.md) | not reported | [(1.25)](/filings/0001108205-26-000061.md) | [(13.61)](/filings/0001108205-26-000118.md) | [(0.49)](/filings/0001108205-25-000107.md) | not reported | [(1.25)](/filings/0001108205-26-000061.md) | [(4.02)](/filings/0001108205-26-000118.md) |
| Basic EPS | $ per share | [(2.13)](/filings/0001108205-24-000072.md) | not reported | [(2.05)](/filings/0001108205-25-000046.md) | [(2.03)](/filings/0001108205-25-000080.md) | [(1.70)](/filings/0001108205-25-000107.md) | not reported | [(1.25)](/filings/0001108205-26-000061.md) | [(13.61)](/filings/0001108205-26-000118.md) | [(0.49)](/filings/0001108205-25-000107.md) | not reported | [(1.25)](/filings/0001108205-26-000061.md) | [(4.02)](/filings/0001108205-26-000118.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.5](/filings/0001108205-24-000072.md) | [26.7](/filings/0001108205-25-000031.md) | [30.0](/filings/0001108205-25-000046.md) | [10.0](/filings/0001108205-25-000080.md) | [20.9](/filings/0001108205-25-000107.md) | [20.0](/filings/0001108205-26-000043.md) | [20.3](/filings/0001108205-26-000061.md) | [10.1](/filings/0001108205-26-000118.md) | [9.1](/filings/0001108205-25-000107.md) | [5.1](/filings/0001108205-26-000118.md) | [15.0](/filings/0001108205-26-000061.md) | [5.1](/filings/0001108205-26-000118.md) |
| Current assets | $m | [73.4](/filings/0001108205-23-000074.md) | [60.9](/filings/0001108205-25-000031.md) | [46.1](/filings/0001108205-24-000033.md) | [34.5](/filings/0001108205-24-000062.md) | [26.9](/filings/0001108205-24-000072.md) | [26.4](/filings/0001108205-26-000043.md) | [24.8](/filings/0001108205-25-000046.md) | [14.4](/filings/0001108205-25-000080.md) | [13.9](/filings/0001108205-25-000107.md) | [6.9](/filings/0001108205-26-000118.md) | [16.6](/filings/0001108205-26-000061.md) | [6.7](/filings/0001108205-26-000118.md) |
| Total assets | $m | [90.0](/filings/0001108205-23-000074.md) | [77.3](/filings/0001108205-25-000031.md) | [62.0](/filings/0001108205-24-000033.md) | [50.4](/filings/0001108205-24-000062.md) | [42.5](/filings/0001108205-24-000072.md) | [41.3](/filings/0001108205-26-000043.md) | [39.3](/filings/0001108205-25-000046.md) | [29.2](/filings/0001108205-25-000080.md) | [27.6](/filings/0001108205-25-000107.md) | [20.0](/filings/0001108205-26-000118.md) | [29.7](/filings/0001108205-26-000061.md) | [19.0](/filings/0001108205-26-000118.md) |
| Current liabilities | $m | [13.7](/filings/0001108205-23-000074.md) | [22.0](/filings/0001108205-25-000031.md) | [11.3](/filings/0001108205-24-000033.md) | [19.4](/filings/0001108205-24-000062.md) | [22.0](/filings/0001108205-24-000072.md) | [19.0](/filings/0001108205-26-000043.md) | [20.1](/filings/0001108205-25-000046.md) | [19.4](/filings/0001108205-25-000080.md) | [19.9](/filings/0001108205-25-000107.md) | [14.1](/filings/0001108205-26-000118.md) | [15.0](/filings/0001108205-26-000061.md) | [13.7](/filings/0001108205-26-000118.md) |
| Total liabilities | $m | [60.4](/filings/0001108205-23-000074.md) | [57.6](/filings/0001108205-25-000031.md) | [52.6](/filings/0001108205-24-000033.md) | [51.1](/filings/0001108205-24-000062.md) | [51.2](/filings/0001108205-24-000072.md) | [47.3](/filings/0001108205-26-000043.md) | [45.9](/filings/0001108205-25-000046.md) | [43.2](/filings/0001108205-25-000080.md) | [42.3](/filings/0001108205-25-000107.md) | [14.5](/filings/0001108205-26-000118.md) | [17.0](/filings/0001108205-26-000061.md) | [14.3](/filings/0001108205-26-000118.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [8.5](/filings/0001108205-25-000031.md) | not reported | not reported | not reported | [7.6](/filings/0001108205-26-000043.md) | [7.2](/filings/0001108205-25-000046.md) | [7.4](/filings/0001108205-25-000080.md) | [7.0](/filings/0001108205-25-000107.md) | [0.0](/filings/0001108205-26-000043.md) | not reported | not reported |
| Shareholders' equity | $m | [29.6](/filings/0001108205-24-000072.md) | [19.7](/filings/0001108205-26-000043.md) | [9.5](/filings/0001108205-25-000107.md) | [(0.7)](/filings/0001108205-25-000107.md) | [(8.7)](/filings/0001108205-25-000107.md) | [(6.0)](/filings/0001108205-26-000118.md) | [(6.6)](/filings/0001108205-26-000118.md) | [(14.0)](/filings/0001108205-26-000118.md) | [(14.7)](/filings/0001108205-25-000107.md) | [5.5](/filings/0001108205-26-000118.md) | [12.7](/filings/0001108205-26-000118.md) | [4.7](/filings/0001108205-26-000118.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.2) d](/filings/0001108205-24-000072.md) | [(10.2) d](/filings/0001108205-25-000031.md) | [(13.2)](/filings/0001108205-25-000046.md) | [(11.1) d](/filings/0001108205-25-000080.md) | [(5.9) d](/filings/0001108205-25-000107.md) | [(9.3) d](/filings/0001108205-26-000043.md) | [(7.3)](/filings/0001108205-26-000061.md) | [(8.0) d](/filings/0001108205-26-000118.md) | [(5.6) d](/filings/0001108205-25-000107.md) | [(6.4) d](/filings/0001108205-26-000043.md) | [(9.0)](/filings/0001108205-26-000061.md) | [(9.6) d](/filings/0001108205-26-000118.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001108205-23-000074.md) | [0.0 d](/filings/0001108205-24-000010.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [4.7](/filings/0001108205-23-000074.md) | [4.8](/filings/0001108205-24-000033.md) | [4.8](/filings/0001108205-24-000062.md) | [5.7](/filings/0001108205-24-000072.md) | [5.8](/filings/0001108205-25-000046.md) | [5.8](/filings/0001108205-25-000080.md) | [5.9](/filings/0001108205-25-000107.md) | [8.5](/filings/0001108205-26-000061.md) | [0.6](/filings/0001108205-26-000118.md) | [15.7](/filings/0001108205-25-000107.md) | [19.4](/filings/0001108205-26-000061.md) | [2.1](/filings/0001108205-26-000118.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,090,077 at 2026-08-11, from the cover of the [10-Q filed 2026-08-14](/filings/0001108205-26-000118.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.